
UNIMORE

Maria Paola COSTI <costimp@unimore.it>

OHD_Newsletter May25- Hi Maria Paola, read here OHD recent development and future plans

OneHealthDrugs COST Action <onehealthdrugs.events@gmail.com> Rispondi a: onehealthdrugs.events@gmail.com A: mariapaola.costi@unimore.it 16 luglio 2025 alle ore 13:13

If you can't see this newsletter properly, please click here





Action Site COST Action LinkedIn YouTube X-Twitter

In this edition ...

- Open letter by Clara and Elisa
- Ongoing Reporting Help Us Document the Impact of OneHealthdrugs
- OneHealthdrugs recent Events
- ¬ OneHealthdrugs COST Action Awards at the GP2A 2025, Paul Ehrlich MedChem 2025 − Nantes, France − June 12th 2025!
- ¬ Advanced Technologies Integration into Medicinal Chemistry Programs June 30th,2025 Online
- ¬ COST21111 Workshop: Integrating Chemoinformatics and Ecotoxicology for Sustainable Drug Discovery 3–4 July 2025
- Upcoming OneHealthdrugs Events
 - HG4 A Fresh Format for Young Researchers
 - Upcoming OHD Training School Protein Expression & Binding Studies

Message from the Action Chair

June - July 2025

Dear Members of the **OneHealthDrugs** Action,

As summer reaches full swing, I'd like to thank all of you in the OneHealthdrugs network for your remarkable energy and achievements over the past two months. From award-winning research to training initiatives and collaborative events across Europe, it's clear we're not slowing down just because the sun's out.

Whether you're continuing in the lab, joining our online sessions, or taking some well-earned time off, I hope you find a moment to recharge and reflect on the meaningful impact your work is making.

With a series of upcoming conferences, workshops, and training schools, I look forward to our continued collaboration and knowledge exchange.

Let's keep working together to advance sustainable solutions in One Health drug discovery.

Thank you all for your ongoing contributions. Here's to a productive, engaging and—when possible—sunny summer.

by Maria-Paola Costi, Action Chair



Open letter by Clara and Elisa

Clara and Elisa participated the COST connect event reported below:

COST Connect event on "Advancing a Clean and Healthy Environment through Research Collaboration", taking place on 17 and 18 June 2025 at the COST Association premises in Brussels



Learn more at https://www.facebook.com/eco4all.eu/

Dear CA21111 members,

As OHD Ambassadors and young researchers in **medicinal chemistry and veterinary science**, we, Elisa Uliassi and Clara Lima, had the privilege of participating in **COST Connect Event 2025** that was an eye-opening experience. The discussions on environmental health, circular economy, and the role of digital innovation resonated deeply with our mission in **COST Action CA21111 – One Health drugs against parasitic vector borne diseases**.

The event underscored how environmental factors—such as water quality, pollution, and chemical exposure—are inextricably linked to both **human and animal health**. This aligns closely with the **One Health** approach, especially in the context of **vector-borne diseases**, we advocate in our COST Action 21111.

We were particularly inspired by the emphasis on:

- Al and digital tools in environmental monitoring, which could be leveraged for disease surveillance and drug resistance tracking;
- The need for **interdisciplinary collaboration** and capacity-building, which empowers young scientists like us to contribute meaningfully beyond lab work;
- Recognition of pharmaceutical pollutants in the environment—an area directly

relevant to drug development and responsible waste management in our field.

One of the most insightful parts of the event was the presentations by key stakeholders, which added tremendous depth.

- UNEP, through Dr. Zhanyl Moldalieva, emphasized the power of digital tools and AI in tracking pollution and supporting global circular economy efforts.
- European Commission DG Environment, represented by Dr. Joachim
 D'Eugenio, provided a clear roadmap through the European Green Deal,
 addressing water, chemicals, sustainable industry, and digital infrastructure.
- UNESCO, represented by Dr. Irina Pavlova, highlighted the value of science diplomacy, ethical collaboration, and education in addressing planetary health.
- These sessions demonstrated how our scientific research—particularly in drug development, and environmental impact of therapeutics—can directly contribute to European and global policy efforts under the One Health umbrella.

As participant (EU) and rapporteur (CL) in the Interactive Discussion Round on Strengthening One Health Approaches To Environmetal Health, we engaged with pressing questions around the environmental impact of pharmaceuticals and disease control strategies. We explored real challenges:

- How do we reduce pharmaceutical residues in soil and water?
- How can education and public awareness support more sustainable drug use?
- What tools and databases can be better utilized for integrated health monitoring?

These questions sparked dynamic conversations and reinforced our belief that we, as scientists with different expertise and background, play a crucial role in shaping future interdisciplinary solutions. This was a powerful reminder of our responsibility not only in drug development, but in ensuring the environmental safety of those interventions.

This event affirmed that the **OneHealthdrugs** network is well-positioned to contribute meaningfully by integrating environmental considerations into therapeutic innovations and collaborating across sectors for real-world impact.

Our takeaway: solving complex public health challenges requires crossing disciplinary boundaries and actively engaging with policy, education, and innovation ecosystems. We see great value in contributing our scientific expertise to wider environmental efforts and forging cross-sectoral partnerships within the **COST framework and beyond**.

Sincerely, Elisa & Clara

Ongoing Survey - Improving Cross-Disciplinary Communication in OneHealthdrugs



As part of our ongoing efforts to strengthen collaboration across scientific disciplines, we invite all OneHealthdrugs members to participate in an internal survey addressing language and communication barriers within the Action.

This survey seeks to evaluate how scientific jargon and discipline-specific terminology may hinder effective knowledge exchange and teamwork. Insights gained will inform strategies to enhance clarity and streamline communication across the network—key to the success of interdisciplinary research in One Health drug development.

Survey Details

Format: 42 brief questions (multiple choice + open answers)

Duration: Approx. 10-15 minutes

Access: Click here to complete the survey

The questionnaire has been reviewed and approved by the OHD Management and Core Group, and is considered a mandatory activity for all members. It aligns with COST principles on



OneHealthDrugs CA21111 questionnaire on the complexities of interdisciplinary communication and scientific terminology for effective communication in drug development programmes for PVBD

Your response has been recorded

Submit another response

inclusiveness, social balance, and data protection. The anonymised responses will be analysed by members of WG4, WG5, WG6, and HG4.

Thank you in advance for your participation and valuable input.

On behalf of WG4, WG5, WG6 and HG4: Anabela C. da Silva, Clara Lima, David Magri, Elisa Uliassi, Eli Thoré, Gülşah Bayraktar, Godwin Ebiloma, Harry de Koning, Maria Paola Costi

OneHealthdrugs recent Events

June and early July saw strong engagement across the OneHealthdrugs network. Besides, Clara Lima and Elisa Uliassi represented OHD at the COST Connect event in Brussels, where they highlighted the environmental dimensions of drug development, the GP2A 2025 meeting in Nantes showcased outstanding research from our members, with three OHD Award winners recognised for their innovative contributions. We wrapped up the month with a focused workshop on integrating advanced technologies—AI, omics, and screening platforms—into medicinal chemistry, reinforcing our mission to deliver effective, environmentally responsible therapeutics.

OneHealthdrugs COST Action Awards at the GP2A 2025, Paul Ehrlich MedChem 2025 & COST Action OneHealthdrugs - Nantes, France - June 12th 2025!



ONEHEALTHDRUGS COST Action AWARDS

France



has been awarded for the CAREER PROMOTION IN ANTIPARASITIC TOPIC



One-Healthdrugs Award
33** GP₂A Annual Conference - COST Action One-Healthdrugs
XIV** Paul Ehrlich MedChem Euro-PhD Network Meeting
This is to certly that

Huseyin Kosker
has been awarded for the
EXCELLENT RESEARCH IN ANTIPARASITIC TOPIC



has been awarded for the EXCELLENT RESEARCH IN ANTIPARASITIC TOPIC

In the presence of over 100 participants, the COST Action OneHealthdrugs sessions at GP2A 2025 and Paul Ehrlich MedChem in Nantes were a great success.


Congratulations to the winners of this year's OHD Awards, whose outstanding work truly stood out:

- Lhana Tisseur Modulation of positions 2 or 8 of the imidazo[1,2-a]pyrazine lead CTN1122 influences its antileishmanial properties, L-CK1.2 kinase inhibition and its safety profile
- **Huseyin Kosker** Synthesis, Structure Elucidation, Antimicrobial and Antiparasitic Activities of New Piperidinhydrazide-hydrazone Derivatives
- Maria F. Martins Synthesis and Antiparasitic Evaluation of Thieno[2,3b]pyrazine Derivatives

See the full announcement here: https://lnkd.in/dcCxjXdc

Thank you to all who took part—your contributions made the session truly impactful.

Advanced Technologies Integration into Medicinal Chemistry Programs June 30th, 2025 Online, from 14:00 to 16:30 CET



This interactive workshop brought together researchers to explore how Al-driven drug design, high-throughput screening, and omics technologies can reshape medicinal chemistry pipelines. With a clear focus on vector-borne diseases in both human and veterinary contexts, the session aligned with the OneHealthdrugs mission of advancing cross-species efficacy while minimising environmental impact. Participants shared insights on accelerating discovery, improving target specificity, and enabling cross-disciplinary collaboration.

More details available at: onehealthdrugs.com/events/scientific-meeting/next-meeting



COST21111 Workshop: Integrating Chemoinformatics and Ecotoxicology for Sustainable Drug Discovery - 3-4 July 2025

Held in collaboration with the Erasmus Mundus Chemoinformatics+ (EMJM) project, this workshop gathered experts in chemoinformatics, toxicology, and sustainable drug discovery. The event highlighted emerging methods for integrating environmental impact into early drug design.

Alongside the main sessions, Maria Paola Costi introduced an upcoming hackathon focused on "10 Targets for Medicinal Chemistry Projects," involving master's students and early-career researchers. While initial outcomes are exploratory, this initiative marks a valuable starting point for collaborative research and innovation within parasitic disease drug discovery.

Upcoming OneHealthdrugs Events

HG4 - A Fresh Format for Young Researchers

Next session: 24 July 2025 (online)

The HG4 Horizontal Group for Young Researchers and Investigators is relaunching its activities with a new interactive format designed to boost collaboration, learning, and idea generation. The upcoming online session will focus on real-world case studies in vector-borne parasitic diseases, presented by early-career scientists across themes like computational chemistry, pharmacology, ecotoxicology, and more.

Each session will include structured peer feedback to promote open dialogue and skill-building. The series begins with Daniele Aiello on 24 July, followed by Ivan Bassanini in September.

Participants are also encouraged to join the HG4 team, as a call for a new vice-leader is now open (Clara Lima is stepping down).

Innovative Approaches to Vector-Borne Parasitic Disease



Key aspects discussed include:

Purpose: The session aims to foster cooperation and collaboration, allowing participants to learn and interact with individuals from diverse backgrounds and expertise. It's described as a "win-win situation" where everyone benefits from the exchange of knowledge. The overall goal is to help solve "real complex problems."

Logistics: Elisa Uliassi plans to send an email with a Doodle poll to determine the most suitable day for the session, ensuring maximum participation.

Expected Outcomes: It is hoped that the session will generate "some new ideas" and help "improve our work."

Participation: Elisa Uliassi expressed her hope that the group's young researcher members, estimated to be about 100, would attend these sessions, highlighting that their contribution is "highly valuable."

Young Researchers' interactive learning sessions Objectives



Organization of interactive learning session focused on vector-borne parasitic diseases, with a special emphasis on the active involvement of young researchers. The core idea is to provide a platform for early-career scientists to present their own real case studies around key thematic areas (Computational, Medicinal and Green Chemistry, Pharmacology and Parasitology, Ecotoxicology...), fostering peer-to-peer learning and encouraging interdisciplinary dialogue.



YRI learning session

A discussion was held on how to organize YRI learning sessions. The sessions will be organized to actively engage young researchers in interdisciplinary learning focused on vector-borne parasitic diseases. Early-career scientists will present real-world case studies under thematic areas such as Computational, Medicinal and Green Chemistry, Pharmacology and Parasitology, and Ecotoxicology. This formed the core of Interactive Activity: Case Study Presentations, encouraging peer-led learning and diverse scientific perspectives. Each presentation will be followed by a structured Peer Review & Feedback segment, promoting critical thinking, constructive dialogue, and collaborative problem-solving. The format successfully will empower YRI to refine their communication skills while fostering cross-disciplinary insights, as well as increase young researchers' participation across all activities.

We agreed to start with Daniele Aiello on 24 July and then proceed with Ivan Bassanini on September.

Participants provided initial feedback and expressed support for the initiatives, emphasizing the need for clear communication and active promotion.

Composition and Management of the YRI Horizontal Group

Call for volunteers to join HG4 team and replace Clara Lima for HG4 vice-leader position. Discussion postponed.

Upcoming OHD Training School - Protein Expression & Binding Studies

8–10 September 2025 | Riga, Latvia Application Deadline: 22 July

Hosted at the Latvian Institute of Organic Synthesis, this hands-on training school will focus on the expression, purification, and biophysical characterisation of protein samples for drug binding studies. Participants will gain practical experience in bacterial expression systems, chromatography techniques, and rapid assessment tools like SDS-PAGE, Circular Dichroism, DSF, and Mass Spectrometry.

Designed for early-career researchers, the course blends lectures with lab-based activities to build foundational skills in evaluating protein stability and ligand interactions —critical steps in drug discovery.

Apply by 22 July: <u>Training School Info</u>

Questions? Contact: atis@osi.lv and Sheraz.Gul@itmp.fraunhofer.de

Give us your valuable feedback

We will be pleased to answer any questions you may have or consider suggestions for improving our Community.

Please email us at onehealthdrugs.events@gmail.com

Contact us if you have any questions, suggestions or you wish to share your news

OneHealthdrugs Academy - Ambassadors Announced!

in D 🛚 🗸 🗗

CA21111 - One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthdrugs)

Unsubscribe me | Change my information